



# MINNESOTA BOARD OF PHARMACY

## Report to the Legislature on the Minnesota Insulin Safety Net Program. (In compliance with Minnesota Statutes Section 151.74, Subd. 13)

*Cody Wiberg, Pharm.D.,  
M.S., R.Ph.*

*Executive Director  
Minnesota Board of  
Pharmacy*

*2829 University Avenue  
SE #530  
Minneapolis, MN 55414*

*(651)201-2825*

*[cody.wiberg@state.mn.us](mailto:cody.wiberg@state.mn.us)*

Revised  
March 22, 2021

## **COST OF REPORT**

[Minnesota Statutes §3.197](#) states that a “report to the legislature must contain, at the beginning of the report, the cost of preparing the report, including any costs incurred by another agency or another level of government”. The estimated cost of preparing this report was **\$380.85**. That is the approximate value, in terms of salary and benefits, of the time that Board staff spent preparing the report.

*(The rest of this page is intentionally blank).*

## Introduction

The Board of Pharmacy (Board) is submitting this report to the Legislature in compliance with Minn. Stats. §151.74, subdivision 13, which states:

Subd. 13. **Reports.** (a) By February 15 of each year, beginning February 15, 2021, each manufacturer shall report to the Board of Pharmacy the following:

- (1) the number of Minnesota residents who accessed and received insulin on an urgent-need basis under this section in the preceding calendar year;
- (2) the number of Minnesota residents participating in the manufacturer's patient assistance program in the preceding calendar year, including the number of Minnesota residents who the manufacturer determined were ineligible for their patient assistance program; and
- (3) the value of the insulin provided by the manufacturer under clauses (1) and (2).

For purposes of this paragraph, "value" means the wholesale acquisition cost of the insulin provided.

(b) By March 15 of each year, beginning March 15, 2021, the Board of Pharmacy shall submit the information reported in paragraph (a) to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services policy and finance. The board shall also include in the report any administrative penalties assessed under subdivision 10, including the name of the manufacturer and amount of the penalty assessed.

## Reporting By Manufacturers

The three manufacturers participating in the Minnesota Insulin Safety Net Program are Eli Lilly and Company, Sanofi, and Novo Nordisk. All three manufacturers submitted the required data by the February 15, 2021 deadline. The data and other information reported are provided below.

The data submitted indicates that, collectively, **the three manufacturers provided insulin under the Minnesota Insulin Safety net Program to as many as 465 residents.** Since some residents may have received insulin under both the Urgent and Continuing Needs Programs, fewer total residents may have benefited. **The total value of the insulin received by residents was \$2,148,564.74.** (Based on the wholesale acquisition cost of the insulin – not the cost that the residents would have paid if they had purchased the insulin on their own). Note that the Board interpreted “the number of Minnesota residents participating in the manufacturer's patient assistance program in the preceding calendar year” to refer to the Continuing Need Programs established by the manufacturers to comply with Minnesota Statutes §151.74 – not to their pre-existing patient assistance programs. Consequently, additional Minnesota residents may have benefited from those programs.

### Eli Lilly

Eli Lilly provided the following information with the submission of its report:

“Please see the report below in response to Minn. Stat. 151.74(13)(a).

The report reflects participation in Lilly’s Minnesota patient assistance programs only (i.e., the programs created to comply with the statute). As you know, Lilly offers a number of other affordability solutions for patients. Minnesota residents may have accessed Lilly insulin through Lilly’s other assistance programs, and these patients (and the value of the associated insulin) are not included in the report.

Also, please note a patient may have applied to the continuing care program to receive more than one product (e.g., a basal and a meal-time insulin), or used the urgent needs program for more than one product. In those cases, we only counted the patient one time in the program.”

Urgent Need Recipients+	91
Value of Insulin Provided to Urgent Need Recipients	\$39,168.28
Number of MN residents participating in patient assistance program*	
Total number of applicants	13
Total number of ineligible applicants	1
Value of Insulin Provided to Continuing Need Recipients	\$28,922.91
Total Value of Insulin Provided	\$68,091.19

**Notes (from Lilly):**

**+Includes two sets of patients in the MN urgent need program: 1) patients who used the urgent needs copay card, and 2) patients who were dispensed product for which the pharmacy sought replacement product (Eli Lilly believes to be ZERO as of 2/12/2021).**

**\*Includes two sets of patients in the MN continuing need PAP: 1) patients who ordered product at their pharmacy, and 2) patients who used the continuing needs copay card.**

Novo Nordisk

Novo Nordisk provided the following data:

Urgent Need Recipients	61
Value of Insulin Provided to Urgent Need Recipients	\$50,509.03
Continuing Need Applicants	
Total number of applicants	227
Total number of ineligible applicants	12
Value of Insulin Provided to Continuing Need Recipients	\$1,952,562.33
Total Value of Insulin Provided	\$2,003,071.36

Sanofi

Sanofi provided the following submission notes:

- WAC = Wholesale Acquisition Cost
- The below figures are reflective of the Minnesota mandated programs that Sanofi offers only and do not include data for any other Sanofi-run program
- \*The "manufacturer's patient assistance program" in Clause 2 below is only referring to the Minnesota mandated program that Sanofi offers

Sanofi provided the following data:

Urgent Need Recipients	142
Value of Insulin Provided to Urgent Need Recipients	\$69,321.00
Continuing Need Applicants* (Clause 2)	
Total number of applicants	3
Total number of ineligible applicants	0
Value of Insulin Provided to Continuing Need Recipients	\$8,081.19
Total Value of Insulin Provided	\$77,402.19

**Assessment of Civil Penalties**

The three insulin manufacturers complied with the provisions of Minn. Stats. §151.74. Consequently, the Board did not assess any civil penalties under subdivision 10.